Literature DB >> 28986612

[Imaging of locally advanced prostate cancer : Importance of ultrasound and especially MRI].

O Solyanik1, B Schlenker2, C Gratzke2, B Ertl-Wagner1, D A Clevert1, C Stief2, J Ricke1, D Nörenberg3.   

Abstract

Prostate cancer is the most common male malignant tumor in Germany, which thus places growing demands on differentiated imaging and risk-adapted therapeutic approaches. Multiparametric MRI (mpMRI) of the prostate enables reliable detection of clinically significant cancers and is currently the leading imaging modality for the detection, characterization, and local staging of prostate cancer. According to the German S3 guideline, mpMRI of the prostate is currently primarily recommended in patients with previous negative TRUS biopsies and persisting tumor suspicion. The serial use of mpMRI in the pretherapeutic setting can support individual therapy planning of patients with locally advanced prostate cancer in the near future.

Entities:  

Keywords:  Extraprostatic extension; Lymph node metastasis; Neoplasm metastasis; Tumor extension; Tumor staging, local

Mesh:

Year:  2017        PMID: 28986612     DOI: 10.1007/s00120-017-0515-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  51 in total

1.  Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging.

Authors:  Leonardo Kayat Bittencourt; Geert Litjens; Christina A Hulsbergen-van de Kaa; Baris Turkbey; Emerson Leandro Gasparetto; Jelle O Barentsz
Journal:  Radiology       Date:  2015-04-03       Impact factor: 11.105

2.  Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy.

Authors:  Hakmin Lee; Chan Kyo Kim; Byung Kwan Park; Hyun Hwan Sung; Deok Hyun Han; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hyun Moo Lee
Journal:  World J Urol       Date:  2016-10-13       Impact factor: 4.226

Review 3.  The role of MRI in prostate cancer diagnosis and management.

Authors:  Neil Mendhiratta; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Future Oncol       Date:  2016-09-19       Impact factor: 3.404

4.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

Review 5.  Prostate cancer: top places where tumors hide on multiparametric MRI.

Authors:  Andrew B Rosenkrantz; Sadhna Verma; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2015-04       Impact factor: 3.959

Review 6.  Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer.

Authors:  Rajan T Gupta; Benjamin Spilseth; Nayana Patel; Alison F Brown; Jinxing Yu
Journal:  Abdom Radiol (NY)       Date:  2016-05

7.  Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.

Authors:  Liang Wang; Hedvig Hricak; Michael W Kattan; Lawrence H Schwartz; Steven C Eberhardt; Hui-Ni Chen; Peter T Scardino
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

Review 8.  Imaging prostate cancer: a multidisciplinary perspective.

Authors:  Hedvig Hricak; Peter L Choyke; Steven C Eberhardt; Steven A Leibel; Peter T Scardino
Journal:  Radiology       Date:  2007-04       Impact factor: 11.105

Review 9.  PI-RADS version 2: what you need to know.

Authors:  T Barrett; B Turkbey; P L Choyke
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

10.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.